Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
229
Frequently Asked Questions
What is Market Cap of Allogene Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Allogene Therapeutics Inc market cap is $259.6M.
What is the 52-week high for Allogene Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Allogene Therapeutics Inc 52 week high is $3.78 as of September 12, 2025.
What is the 52-week low for Allogene Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Allogene Therapeutics Inc 52 week low is $0.8621 as of September 12, 2025.
What is Allogene Therapeutics Inc stock price today?
Allogene Therapeutics Inc stock price today is $1.13.
What was Allogene Therapeutics Inc stock price yesterday?
Allogene Therapeutics Inc stock price yesterday was $1.17.
What is the PE ratio of Allogene Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Allogene Therapeutics Inc’s P/E ratio is -1.05.
What is the Price-to-Book ratio of Allogene Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Allogene Therapeutics Inc P/B ratio is 0.7475.
What is the 50-day moving average of Allogene Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Allogene Therapeutics Inc 50-day moving average is $1.19.
How many employess does Allogene Therapeutics Inc has?